1.
EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium
by Bart, Pierre-Alexandre
Vaccine, 2008, Vol.26 (25), p.3153-3161

2.
CCR5 targeted SIV vaccination strategy preventing or inhibiting SIV infection
by Bogers, W.M.J.M
Vaccine, 2004, Vol.22 (23), p.2974-2984

3.
Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates
by Verstrepen, Babs E
Vaccine, 2008, Vol.26 (26), p.3346-3351

4.
Decreased expression of IL-2 in central and effector CD4 memory cells during progression to AIDS in rhesus macaques
by KOOPMAN, Gerrit
AIDS (London), 2001, Vol.15 (18), p.2359-2369

5.
Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model
by Suh, You S
Vaccine, 2006, Vol.24 (11), p.1811-1820

6.

7.

8.
Stimulation of both humoral and cellular immune responses to HIV-1 gp120 by interleukin-12 in Rhesus macaques
by van der Meide, Peter H
Vaccine, 2002, Vol.20 (17), p.2296-2302

9.
In vitro replication of SIVcpz is suppressed by β-chemokines and CD8+ T cells but not by natural killer cells of infected chimpanzees
by ONDOA, Pascale
AIDS research and human retroviruses, 2002, Vol.18 (5), p.373-382

10.
HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees
by Bruck, Claudine
Vaccine, 1994, Vol.12 (12), p.1141-1148

11.
